#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to early-stage data presented Friday at the annual meeting of the European Society of Cardiology. The company will ...
ESC Congress in Munich (Elizabeth Cairns for Endpoints News) August 28, 2026 10:30 AM EDTUpdated 11:12 AM R&DCell/Gene Tx CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy Elizabeth Cairns Senior biopharma journalist MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to early-stage data presented Friday at the annual … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that